fMRI and qEEG studies
Upcoming SlideShare
Loading in...5
×

Like this? Share it with your network

Share
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
693
On Slideshare
691
From Embeds
2
Number of Embeds
1

Actions

Shares
Downloads
9
Comments
0
Likes
0

Embeds 2

http://rdsyndrome.com 2

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Acute Intravenous Synaptamine Patient 1 “Before”
  • 2. Acute Intravenous Synaptamine Patient 1 “After”
  • 3. Acute Intravenous Synaptamine Patient 2 “Before”
  • 4. Acute Intravenous Synaptamine Patient 2 “After”
  • 5. qEEG STUDIES Subject 1.1: Baseline EEG (Fiq. 1) Baseline EEG analyses shows increased widespread theta (4-8hz) and increased frontal beta (12-25hz) compared to the norm. Widespread increased theta is associated with metabolic disturbance/dysregulation and increased frontal beta is associated with mood disturbance, over-arousal, and anxiety. These features are often associated with anxious, obsessive behaviors, anger, and difficulty de-escalating when upset.  
  • 6. qEEG STUDIES Subject 1.1: Post Amino Acid EEG (Fig. 2) Post EEG analyses shows decreased frontal theta (4-8hz) and decreased frontal beta (12-15hz) indicating improved functioning immediately post amino acid intravenous treatment. When individual frequencies are reviewed changes are noted in more detail compared to the norm.     
  • 7. qEEG STUDIES BEFORE AFTER
  • 8. qEEG STUDIES Subject 1.2: Baseline EEG (Fig. 3) Note increased widespread theta from 4-7 Hz and increased frontal/central beta at 15-16 Hz.  
  • 9. qEEG STUDIES Subject 1.2: Post Amino Acid EEG (Fig. 4) Post intravenous amino acid treatment decreased widespread theta at 4-7 Hz and at 15-16 Hz indicating improved functioning. Subject 2: 24 year old male with a history of opiate addiction. Subject was medication and drug free for 30 days prior to the study. Labeling: Subject 2.1 is pre treatment assessment. Subject 2.2 is post treatment of Subject 2.    
  • 10. qEEG STUDIES BEFORE AFTER
  • 11. Oral Synaptamine a. P-Values Group 1 vs. Group 2: Week 1 b. P-Values Group 1 vs. Group 2: Week 2
  • 12.
    • In 600 patients, enhancement of cognitive processing, reduction of anxiety, increased concentration, reduction in anger, reduction in depression, increased energy, and reduction in fatigue were observed.(1)
    • Claims ( Please provide actual data ):
    • Acute IV therapy determined the mechanism of action of Synaptamine in an alcoholic and heroin abuser whereby existing abnormalities (i.e. widespread theta and widespread alpha activity respectively) during protracted abstinence are “normalized. (2)
    • References:
    • 1 Blum et al. SG839-an amino –acid enkephalinase inhibition nutraceutical improves recovery of alcoholics. A subtype of RDS . Trends in Applied Sciences Res. 2(2) 132-138, 2007.
    • 2 Miller et al. Acute Intravenous Synaptamine Complex [KB220]™ Variant “Normalizes” Abnormal Neurological Activity in Protracted Abstinence of Alcohol and Opiate Patients Using Quantitative Electroencephalographic (QEEG) and Neurotransmitter Genetic Analysis: Pilot Two Case Reports Postgraduate Medicine (in Press).
  • 13. NEUROIMAGING STUDIES Resting–State fMRI After One Dose Synaptamine (n=5) Placebo (n=5)